Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIG-MOON: Metronomic Capecitabine Maintenance in mCRC
NCT03158610Phase 3Terminated
- Sponsor
- Ruijin Hospital
- Start
- Jan 2018
- Primary completion
- Apr 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Progression Free Survival 1 at 10 months and Progression Free Survival 2 at 4 months. Started Jan 2018; status: terminated.
02
Drugs
capecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03158610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158610.